AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00534404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Description: Participants will wear nicotine patches.
Study NCT00534404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Participants will wear nicotine patches.
Study NCT00534404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
Study NCT00534404 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: iQuit Smoking website
Description: Participants will access the Project Quit (iQuit Smoking) website.
Study NCT00534404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iQuit Smoking website
Description: Participants will access the Project Quit (iQuit Smoking) website.
Study NCT00534404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iQuit Smoking website
Description: Participants will access the Project Quit (iQuit Smoking) website.
Study NCT03977714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia implants with G3-coated abutments (test implants and abutments)
Description: Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.
Study NCT03977714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia implants with control abutments (test implants, negative control abutments)
Description: Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.
Study NCT03977714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium implants with G3-coated abutments (control implants, test abutments)
Description: Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.
Study NCT03977714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium implants with control abutments (negative control implants and abutments)
Description: Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected.
Study NCT03977714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia implants and titanium implants, for histological and histomorphometric evaluation.
Description: 6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary.
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique, Inexperienced group
Description: This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
Study NCT03612349 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental Tobacco Marketplace Task
Description: Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
Study NCT03349983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury/ FPV-Brachyury
Description: Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
Study NCT04993066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleMax Pro Plus
Description: The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
Study NCT00811928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole
Description: 40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)
Study NCT00811928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)
Study NCT01039610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK945237
Description: Dose detailed in Arm description
Study NCT01039610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study NCT01039610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study NCT01933126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG injection
Study NCT01933126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00661024 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intraoperative RLN visualization
Description: intraoperative RLN visualization
Study NCT00661024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative neuromonitoring of the RLN
Description: IONM
Study NCT01767077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Butter oil
Description: Daily intake of 40 g butter oil
Study NCT01767077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cream
Description: Daily intake of 100 g cream (40%)
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique, Inexperienced group
Description: This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
Study NCT04534101 — intervention group
Intervention type: BEHAVIORAL
Intervention: Virtual Reality Mindfulness
Description: This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
Study NCT02844335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02844335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02844335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study NCT03116542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic (18F-FLT PET/CT)
Description: The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
Study NCT01891344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rucaparib
Description: 600 mg BID
Study NCT01359605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: 500 mg oral suspension
Study NCT01198457 — intervention group
Intervention type: DRUG
Intervention: Clodronate (Bonefos, BAY94-8393)
Description: Random group of patients in oncology clinic
Study NCT02816203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic Intra-Uterine suction cup
Description: The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
Study NCT01414205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
Study NCT01414205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Participants were administered corticosteroids IV prior to the initial dose.
Study NCT02211118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal dexemdetomidine (IN-DEX)
Study NCT02767479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole-based regimen
Description: This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
Study NCT02767479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole^based regimen
Description: This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
Study NCT02933567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSC OnDemand
Description: CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
Study NCT00054691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa
Description: 250 mg by mouth daily
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-axis technique
Description: Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis technique
Description: Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-axis technique
Description: Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
Study NCT01696279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Description: Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
Study NCT01696279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
Study NCT03077802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-axis technique
Description: Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
Study NCT02029833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Canola Oil
Study NCT02029833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Oleic Canola Oil
Study NCT02029833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western Type Diet - Common Dietary Oils
Study NCT04028076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence
Description: An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
Study NCT04723381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based education
Description: Expert support and consultancy were received for the design and preparation of the web page.
Study NCT04798547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Myotomy
Description: Evaluation of short length myotomy
Study NCT03115021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
Study NCT04798547 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Length Myotomy
Description: Standard Length Myotomy
Study NCT01108601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ringer's Lactate (0.03% Ciprofloxacin)
Description: For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
Study NCT03959293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg by 1-hour IV infusion - Every 4 weeks
Study NCT03959293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg by 1-hour IV infusion - Every 4 weeks
Study NCT03959293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: * Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion
Study NCT01216527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemoradiotherapy followed by Surgery
Description: 1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy
Study NCT01216527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: two field lymphadenectomy
Study NCT04372667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community score card approach
Description: The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up
Study NCT02461108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsidy
Description: Frame the price difference as a 10% subsidy on nutritious food items.
Study NCT02461108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tax
Description: Frame the price difference as a 10% tax on less nutritious food items.
Study NCT02461108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tax and subsidy
Description: Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
Study NCT01647412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
Study NCT01647412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Combination
Study NCT01647412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutraceutical Combination
Study NCT01647412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusion Diet
Description: Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.